Pitavastatin: Evidence for its place in treatment of hypercholesterolemia

Core Evidence

Volumn 5, Issue , 2010, Pages 91-105

  Alagona Jr , Peter ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Class effect; HMG CoA reductase inhibitors; Low density lipoprotein; Pitavastatin; Statins

Indexed keywords

AMIODARONE; ANTIDEPRESSANT AGENT; APOLIPOPROTEIN B; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN; CYTOCHROME P450 3A4; DILTIAZEM; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROLIDE; MEVINOLIN; PITAVASTATIN; PLACEBO; PRAVASTATIN; PYRROLE DERIVATIVE; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; VERAPAMIL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; WARFARIN;

ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG RETENTION; DRUG SAFETY; GLYCEMIC CONTROL; GRAPEFRUIT JUICE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INTRAVASCULAR ULTRASOUND; MONOTHERAPY; MUSCLE DISEASE; MYALGIA; MYOGLOBINURIA; PATIENT COMPLIANCE; PLEIOTROPY; POSTMARKETING SURVEILLANCE; PROTEIN BINDING; PROTEIN BLOOD LEVEL; REVIEW; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

EID: 79959365595     PISSN: 15551741     EISSN: None     Source Type: Journal    
DOI: 10.2147/CE.S8008     Document Type: Review

References (86)

1. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res. 1992;33:1569-1582.
2. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science. 2001;292:1160-1164. (Pubitemid 32440937)
3. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232:34-47. (Pubitemid 16037973)
4. Arad Y, Ramakrishnan R, Ginsberg HN. Lovastatin therapy reduces low-density lipoprotein apoB levels in subjects with combined hyperlipdemia by reducing the production of apoB containing lipoproteins: Implications for the pathophysiology of apoB production. J Lipid Res. 1990;31:567-582. (Pubitemid 20167624)
5. Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med. 1990;323:946-955. (Pubitemid 20332334)
6. Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial Results II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-374.
7. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-1278.
8. Sukhova GK, Williams JK, Libby P. Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol. 2002;22:1452-1458.
9. Plenge JK, Hernandez TL, Weil KM, et al. Simvastatin lowers C-reactive protein within 14 days: An effect independent of low-density lipoprotein cholesterol reduction. Circulation. 2002:106:1447-1452.
10. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352:29-38. (Pubitemid 40075678)
11. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20-28. (Pubitemid 40075677)
12. Tsunekawa T, Hayashi T, Kano H, et al. Cerivastatin, a hydroxyl-methylglutaryl coenzyme A reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation. 2001;104:376-379. (Pubitemid 32678263)
13. Beckman JA, Liao JK, Hurley S, et al. Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein. Circ Res. 2004;95:217-223. (Pubitemid 38988689)
14. Laufs U, Wassmann S, Hilgers S, et al. Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am J Cardiol. 2001;88:1306-1307. (Pubitemid 33132103)
15. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid lowering therapy on progression of coronary atherosclerosis. JAMA. 2004;291:1071-1080. (Pubitemid 38541684)
16. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: Mechanism and clinical relevance. Clin Pharmacol Ther. 2006;80:565-581. (Pubitemid 44908269)
17. Lilja JJ, Neuvonen M, Neuvonen PJ. Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. Br J Clin Pharmacol. 2004;58:56-60. (Pubitemid 38901467)
18. McKenney JM, Ganz P, Wiggins BS, et al. In: Ballantyne CM, editor. Clinical Lipidology A Companion to Braunwald's Heart Disease. Philadelphia, PA: Saunders Elsevier; 2009.
19. Bays HE, Jones PH, Mohiuddin SM, et al. Efficacy and safety of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia. J Clin Lipidol. 2008;2:426-435. (Pubitemid 352795715)
20. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol. 2003;92:152-160. (Pubitemid 36835963)
21. McKenney JM, Jones PH, Adamczyk MA, et al. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin and pravastatin in achieving lipid goals (STELLAR trial). Curr Med Res Opin. 2003;19:689-698. (Pubitemid 37466137)
22. The National Cholesterol Education Program Expert Panel. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
23. Rosenson R, Otvos JD, Freedman DS. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) Trial. Am J Cardiol. 2002;90:89-94. (Pubitemid 34775113)
24. McKenney JM, McCormick LS, Schaefer EJ, et al. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol. 2001;88:270-274. (Pubitemid 32721954)
25. Sacks FM, Alaupovic P, Moye LA. Effect of pravastatin on apolipoprotein B and C-III in very low-density lipoproteins and low-density lipoproteins. Am J Cardiol. 2002;90:165-167. (Pubitemid 34775129)
26. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet.1994;339:1349-1357.
27. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
28. Heart Protection Study Collaborative Group: Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363:757-767.
29. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomized controlled trial. Lancet. 2002;360:1223-1230.
30. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomized placebo-controlled trial. Lancet. 2004;364:685-697.
31. Neil HA, DeMicco DA, Luo DJ, et al. Analysis of efficacy and safety in patients aged 65-75 years at randomization. Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care. 2006;29:2378-2384.
32. Hayward RA, Hofer TP, Vijan S. Narrative review: Lack of evidence for recommended low-density lipoprotein treatment targets: A solvable problem. Ann Intern Med. 2006;145:520-530. (Pubitemid 46780956)
33. Davidson MH, Maki KC, Pearson JA, et al. Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel-E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP writing group recommendations. Am J Cardiol. 2005;96:556-563. (Pubitemid 41132774)
34. McCrindle BW, Urbina EM, Dennison BA, et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: A scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation. 2007;115:1948-1967. (Pubitemid 46598908)
35. Saito Y. Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals. Vasc Health Risk Manag. 2009;5:921-936.
36. Kimata H, Fujino H, Koide T, et al. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (1): Absorption, distribution, metabolism and excretion in rats. Drug Metab Pharmacokinet. 1998;13:484-498.
37. Morikawa S, Umetani M, Nakagawa S, et al. Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals. J Atheroscler Thromb. 2000;7:138-144.
38. Aoki T, Nishimura H, Nakagawa S, et al. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Arzneimittelforschung. 1997;47:904-909. (Pubitemid 27357013)
39. Maejima T, Yamazaki H, Aoki T, et al. Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell. Biochem Biophys Res Commun. 2004;324:835-839. (Pubitemid 39345591)
40. Fujino H, Yamada I, Shimada S, et al. Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: Human UDP-glucuronosyl transferase enzymes involved in lactonization. Xenobiotica. 2003;33:27-41. (Pubitemid 36071761)
41. Fujino H, Yamada I, Kojima I, et al. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (5): In vitro metabolism and plasma protein binding in animals and humans. Xenobio Metab Disp. 1999;14:415-424.
42. Nakaya N, Tateno M, Nakamura T, et al. Pharmacokinetics of repeated dose NK-104 (pitavastatin) in healthy elderly and non-elderly volunteers. J Clin Ther Med. 2001;17:957-970. Japanese.
43. Ando H, Tsuruoka S, Yanagihara H, et al. Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. Br J Clin Pharmacol. 2005;60:494-497. (Pubitemid 41532449)
44. Sakaeda T, Fujino H, Komoto C, et al. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm Res. 2006;23:506-512.
45. Kajinami K, Mabuchi H, Saito Y. NK-104 a novel synthetic HMG-CoA reductase inhibitor. Expert Opin Investig Drugs. 2000;9:2653-2661.
46. Jacobson TA. The safety of aggressive statin therapy: How much can low-density lipoprotein cholesterol be lowered? Mayo Clin Proc. 2006;81:1225-1231.
47. Saito Y, Teramoto T, Yamada N, et al. Clinical efficacy of NK-104 (Pitavastatin), a new synthetic HMG-CoA reductase inhibitor, in the dose finding, double blind, three-group comparative study. J Clin Ther Med. 2001;17:829-855. Japanese.
48. Budinski D, Arneson V, Hounslow N, et al. Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia. Clin Lipidol. 2009;4:291-302.
49. Saito Y, Yamada N, Teramoto T, et al. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis. 2002;162:373-379. (Pubitemid 34457943)
50. Park S, Kang HJ, Rim SI, et al. A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia. Clin Ther. 2005;27:1074-1082. (Pubitemid 41262465)
51. Ose L, Budinski D, Hounslow N, et al. Comparison of itavastatin to simvastatin in primary hypercholesterolemia or combined dyslipidemia. Curr Med Res Opin. 2009;25:2817-2828.
52. Nakaya N, Saito Y, Morisaki N, et al. Phase II clinical study of NK-104 (pitavastatin) in patients with hyperlipidemia. J Clin Ther Med. 2001;17:789-806. Japanese.
53. Sasaki J, Ikeda Y, Kuribayashi T, et al. A 52-week, randomized, open label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Clin Ther. 2008;30:1089-1101. (Pubitemid 351978115)
54. Kurihara Y, Douzono T, Kawakita K, et al. A large-scale, long-term prospective post-marketing surveillance of pitavastatin (LIVALO Tablet) - LIVALO Effectiveness and Safety (LIVES) Study. Jpn Pharmacol Ther. 2008;36:709-731.
55. Teramo T, Hitoshi S, Koutaro Y, et al. Effects of Pitavastatin (LIVALO tablet) on high density lipoprotein cholesterol (HDL-C) in hypercholesterolemia: Sub-analysis of LIVALO effectiveness and safety (LIVES) study. J Atheroscler Thromb. 2009;16:654-661.
56. Kawano M, Nagasaka S, Yagyu H, et al. Pitavastatin decreases plasma prebeta-HDL concentration and might promote its disappearance rate in hypercholesterolemic patients. J Atheroscler Thromb. 2008; 15:41-46.
57. Yokote K, Bujo H, Hanaoka H, et al. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atoravastatin in Japanese hypercholesterolemic patients: Collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis. 2008;201:345-352.
58. Nozue T, Michishita I, Ito Y, et al. Effects of statin on small dense low-density lipoprotein cholesterol and remnant-like particle cholesterol in heterozygous familial hypercholesterolemia. J Atheroscler Thromb. 2008;15:146-153.
59. Sone H, Takahashi A, Shimano H, et al. HMG-CoA reductase inhibitor decreases small dense low-density lipoprotein and remnant-like particle cholesterol in patients with type-2 diabetes. Life Sci. 2002;72:2403-2412. (Pubitemid 35264612)
60. Koshiyama H, Taniguchi A, Tanaka K, et al. Kansai investigation of statin for hyperlipidemic intervention in metabolism and endocrinology investigators. Effects of pitavastatin on lipid profiles and high-sensitivity CRP in Japanese subjects with hypercholesterolemia. Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) investigators. J Atheroscler Thromb. 2008;15:345-350.
61. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143. (Pubitemid 34212626)
62. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363-369. (Pubitemid 36158034)
63. Motomura T, Okamoto M, Kitamura T. Effects of pitavastatin on serum lipids and high sensitivity C-reactive protein in type 2 diabetic patients. J Atheroscler Thromb. 2009;16:546-552.
64. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest. 1998;101: 2711-2719. (Pubitemid 28294580)
65. Morikawa S, Takabe W, Mataki C, et al. The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. J Atheroscler Thromb. 2002;9:178-183.
66. Kajinami K, Takekoshi N, Saito Y. Pitavastatin: Efficacy and safety profiles of a novel HMG CoA reductase inhibitor. Cardiovasc Drug Rev. 2003;21:199-215. (Pubitemid 37243525)
67. Kohno M, Shinomiya K, Abe S, et al. Inhibition of migration and proliferation of rat smooth muscle cells by a new HMG-CoA reductase inhibitor, pitavastatin. Hypertens Res. 2002;9:279-285. (Pubitemid 34464458)
68. Suzuki H, Yamasaki H, Aoki T, et al. Lipid lowering and antiatherosclerotic effect of NK-104, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in Watanabe heritable hyperlipidemic rabbits. Arzneimittelforschung. 2000;50:995-1003.
69. Kitahara M, Kanaki T, Toyoda K, et al. NK-104, a newly developed HMG-CoA reductase inhibitor, suppresses neointimal thickening by inhibiting smoooth muscle cell growth and fibronectin production in ballon-injured rabbit carotid artery. Jpn J Pharmacol. 1998;77:117-128. (Pubitemid 28336344)
70. Hiro T, Kimura T, Morimoto T, et al. Effect of intensive statin therapy in regression of coronary atherosclerosis in patients with acute coronary syndrome: A multi-center randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin. (Japan ACS Study). J Am Coll Cardiol. 2009;54:293-302.
71. Takashima H, Ozaki Y, Yasukawa T, et al. Impact of lipid-lowering therapy with pitavastatin, a new HMG-CoA reductase inhibitor, on regression of coronary atherosclerotic plaque. Circ J. 2007;71:1678-1684. (Pubitemid 350240085)
72. Nakamura T, Obata JE, Kitta Y, et al. Rapid stabilization of vulnerable carotid plaque within 1 month of pitavastatin treatment in patients with acute coronary syndrome. J Cardiovasc Pharmacol. 2008;51:365-371. (Pubitemid 351572235)
73. Flores NA. Pitavastatin: Nissan/Kowa Yakuhin/Novartis/Sankyo. Curr Opin Investig Drugs. 2002;3:1334-1341. (Pubitemid 36266756)
74. Elisaf M. XII International Symposium on Atherosclerosis. 2000 Jun 25-29; Stockholm, Sweden. IDrugs. 2000;3:1162-1163.
75. Kurihara Y, Douzono T, Kawakita K, et al. A large-scale, prospective post-marketing surveillance of pitavastatin (LIVALO tablet) - drug use investigation. J Pharmacol Ther. 2000;5:9-40. Japanese.
76. Komano N, Masaki M, Kawai H, et al. The safety and efficacy in post-marketing surveys of atorvastatin. Prog Med. 2005;25:131-142. Japanese.
77. McTaggert F. Comparative pharmacology of rosuvastatin. Atheroscler Suppl. 2003;4:9-14.
78. Kawashiri MA, Nohara A, Tada H, et al. Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia results from a crossover study. Clin Pharmacol Ther. 2008;83:731-739. (Pubitemid 351556020)
79. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + fibrates versus gemfibrozil + any statin. Am J Cardiol. 2005;95:120-122. (Pubitemid 40051126)
80. Davidson MH, Armani A, McKenney JM, et al. Safety considerations with fibrate therapy. Am J Cardiol. 2007;99 Suppl:3C-18C.
81. Grundy SM, Vega GL, Yuan Z, et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (The Safari Trial). Am J Cardiol. 2005;95:462-468. (Pubitemid 40247539)
82. Ellen RLB, McPherson R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combination hyperlipidemia. Am J Cardiol. 1998;81(4A):60B-65B.
83. Jones PH, Bays HE, Davidson MH, et al. Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins. Clin Drug Investig. 2008;28:625-634.
84. Sabatine MS, Wiviott SD, Morrow DA, et al. High-dose atorvastatin associated with glycemic control: A PROVE-IT TIMI 22 substudy. Circulation. 2004;110 Suppl I:S834.
85. Colhoun HM, Betteridge DJ, Durrington PN, et al. CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomized placebo-controlled trial. Lancet. 2004;364:685-696.
86. Kawai T, Tokui M, Funae O, et al. Efficacy of pitavastatin, a new HMG Co A reductase inhibitor, on lipid and glucose metabolism in patients with Type 2 diabetes. Diabetes Care. 2005;28:2980-2981. (Pubitemid 43942938)